GLP-1 Agonists and HIV: Do Weight-Loss Drugs Make Sense for Your Patients?     Three GLP-1 agonist drugs (which originally had been confined to diabetes treatment) are currently FDA approved specifically for weight loss. The rapid uptake of these medications in the U.S. has naturally led to questions within the HIV clinical community about their safety and efficacy in people living with HIV, whose journeys with weight gain and weight loss overlap with the general population but also may differ significantly in a few key ways.     Joining us on the podcast this month to provide some answers is one of the most prominent clinician researchers exploring this topic today: Grace McComsey, M.D., a professor of pediatrics and medicine at Case Western Reserve University, as well as the vice president of research and the associate chief scientific officer at the University Hospitals Health System in Cleveland, Ohio.     Read the transcript: https://www.thebodypro.com/article/future-hiv-care-glp-1-agonists-semaglutide     Credits: Our executive producer is Myles Helfand; our project manager is Alina Mogollon-Volk; our audio producers/engineers are Alex Portaluppi and Lucy Mueller; and our series editors are Maria Elena Perez and Juan Michael Porter II. This episode's audio was edited by Kim Buikema.